These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 16186179

  • 21. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
    Aigelsreiter A, Janig E, Stumptner C, Fuchsbichler A, Zatloukal K, Denk H.
    Pathobiology; 2007; 74(3):145-58. PubMed ID: 17643060
    [Abstract] [Full Text] [Related]

  • 22. Proteopathy: the next therapeutic frontier?
    Walker LC, LeVine H.
    Curr Opin Investig Drugs; 2002 May; 3(5):782-7. PubMed ID: 12090553
    [Abstract] [Full Text] [Related]

  • 23. Membrane permeabilization by Islet Amyloid Polypeptide.
    Engel MF.
    Chem Phys Lipids; 2009 Jul; 160(1):1-10. PubMed ID: 19501206
    [Abstract] [Full Text] [Related]

  • 24. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
    Zhang Q, Zhang X, Sun A.
    Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
    [Abstract] [Full Text] [Related]

  • 25. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones?
    Muchowski PJ.
    Neuron; 2002 Jul 03; 35(1):9-12. PubMed ID: 12123602
    [Abstract] [Full Text] [Related]

  • 26. Domain interactions direct misfolding and amyloid formation of yeast phosphoglycerate kinase.
    Osváth S, Jäckel M, Agócs G, Závodszky P, Köhler G, Fidy J.
    Proteins; 2006 Mar 01; 62(4):909-17. PubMed ID: 16353200
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Conformational change, pore formation and neurotoxicity of amyloidogenic proteins].
    Kawahara M.
    Rinsho Byori; 2008 Feb 01; 56(2):130-6. PubMed ID: 18404827
    [Abstract] [Full Text] [Related]

  • 30. Amyloid-beta aggregation.
    Finder VH, Glockshuber R.
    Neurodegener Dis; 2007 Feb 01; 4(1):13-27. PubMed ID: 17429215
    [Abstract] [Full Text] [Related]

  • 31. Linker histone H1 binds to disease associated amyloid-like fibrils.
    Duce JA, Smith DP, Blake RE, Crouch PJ, Li QX, Masters CL, Trounce IA.
    J Mol Biol; 2006 Aug 18; 361(3):493-505. PubMed ID: 16854430
    [Abstract] [Full Text] [Related]

  • 32. Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options.
    Tillement JP, Lecanu L, Papadopoulos V.
    Pharmacology; 2010 Aug 18; 85(1):1-17. PubMed ID: 19923873
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Mechanisms of disease II: cellular protein quality control.
    Outeiro TF, Tetzlaff J.
    Semin Pediatr Neurol; 2007 Mar 18; 14(1):15-25. PubMed ID: 17331880
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Visual aspects of neurologic protein misfolding disorders.
    Pula JH, Kim J, Nichols J.
    Curr Opin Ophthalmol; 2009 Nov 18; 20(6):482-9. PubMed ID: 19816176
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Imaging protein oligomerization in neurodegeneration using bimolecular fluorescence complementation.
    Herrera F, Gonçalves S, Outeiro TF.
    Methods Enzymol; 2012 Nov 18; 506():157-74. PubMed ID: 22341224
    [Abstract] [Full Text] [Related]

  • 40. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
    Pei JJ, Sjögren M, Winblad B.
    Curr Opin Psychiatry; 2008 Nov 18; 21(6):555-61. PubMed ID: 18852562
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.